Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Consumer OTC Drugs

Allergan first quarter contact lens care sales up 8% due to Pilkington Barnes Hind buy.

This article was originally published in The Tan Sheet

  • News
  • The Tan Sheet

Executive Summary

ALLERGAN CONTACT LENS CARE SALES RISE 8% IN FIRST QUARTER to $91.5 mil., primarily because of the contribution from recently-acquired Pilkington Barnes Hind, the company reported April 17. Excluding $10.1 mil. in sales that came from Pilkington Barnes Hind, Allergan's optical sales fell 4% in the three-month period. Allergan announced the acquisition of Pilkington Barnes Hind in November ("The Tan Sheet" Dec. 4, 1995, p. 7).

Table

View full table

Topics

Tags:
Consumer OTC Drugs
Latest Headlines

Australia Calls For Companion Testing Plans For Drugs Requiring A CDx

Pharma Can Pursue Claims Against Providers For 340B Duplicate Discounts In Medicaid Managed Care, HRSA Says

The Aspirin Test For AI?

Mary Beth Clarke, CDER Exec Programs Office Director And Generic User Fee Shepherd, Will Retire

See All
UsernamePublicRestriction

Register

PS085001

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By